A girl with hepatitis C holds a medical report while being treated at a hospital in Hefei, China, in 2011. China has one of the greatest burdens of hepatitis C, but it's still not clear whether a deal for lower prices for a new drug from Gilead Sciences will apply there. (Barcroft Media/Landov)
